Composition and methods for transdermal delivery of acid labile drugs
First Claim
1. A transdermal composition substantially free of weak organic acids, of lower alkanols and of gestodene, the composition comprising (a) a therapeutically effective amount of a pharmacologically active drug subject to acid catalyzed degradation;
- (b) a pharmaceutically acceptable carrier; and
(c) a penetration enhancing amount of a functional derivative of a fatty acid, wherein said derivative is selected from the group consisting of amides, alcohols, and polyols.
1 Assignment
0 Petitions
Accused Products
Abstract
A transdermal composition and related method are described. Specifically, the transdermal composition is substantially free of gestodene or substantially free of isopropyl myristate and substantially free of lower alkanols and comprises: (a) a therapeutically effective amount of a pharmacologically active drug which is subject to acid catalyzed degradation; (b) a pharmaceutically acceptable carrier; and (c) a penetration enhancing effective amount of a functional derivative of a fatty acid.
-
Citations
18 Claims
-
1. A transdermal composition substantially free of weak organic acids, of lower alkanols and of gestodene, the composition comprising (a) a therapeutically effective amount of a pharmacologically active drug subject to acid catalyzed degradation;
- (b) a pharmaceutically acceptable carrier; and
(c) a penetration enhancing amount of a functional derivative of a fatty acid, wherein said derivative is selected from the group consisting of amides, alcohols, and polyols. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- (b) a pharmaceutically acceptable carrier; and
-
11. A method of enhancing the penetration of a pharmacologically active drug comprising topically applying to a mammal a composition comprising:
- (a) a therapeutically effective amount of a pharmacologically active drug which is subject to acid catalyzed degradation;
(b) a pharmaceutically acceptable carrier; and
(c) a penetration enhancing effective amount of a functional derivative of a fatty acid, wherein said derivative is selected from the group consisting of amides, alcohols, and polyols, and wherein said composition is substantially free of weak organic acids, of lower alkanols, and of gestodene. - View Dependent Claims (12)
- (a) a therapeutically effective amount of a pharmacologically active drug which is subject to acid catalyzed degradation;
- 13. A stabilized patch device for transdermal delivery of a steroid drug containing a 3-keto-4-en functional group, wherein said steroid drug is stable upon extended storage of said device, comprising an effective amount of said steroid drug and a carrier, wherein said carrier has no acid functional groups and forms no acid functional groups upon storage, and wherein said carrier is substantially free of weak organic acids, of lower alkanols, and of gestodene.
-
18. The stabilized patch device of calim 17, wherein said progestin is norethindrone acetate.
Specification